Newly reported from ACC 2024: Inclisiran First Strategy Safe, Effective for LDL-C Control in ASCVD Patients
Use of an inclisiran (Leqvio) first implementation strategy among patients with atherosclerotic cardiovascular disease and an LDL-C at 70 or greater was associated with a significant reduction in LDL-C relative to usual care, without incurring safety concerns or limiting statin use, according to a study presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions.
Results of the VICTORION-INITIATE trial indicate use of an inclisiran first strategy was associated with a more than tripling in the rate of patients achieving their LDL-C target goal and noninferior statin discontinuation rates relative to their counterparts receiving usual care.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
